January 2013
Hawaii Journal of Medicine & Public Health;Jan2013, Vol. 72 Issue 1, p34
Academic Journal
The article offers news briefs on several topics related to the U.S. as of January 2013. The U.S. Preventative Services Task Force (USPSTF) approves that citizen of the country from age group 15 to 65 should be tested for HIV. A group of prisoners is admitted to a hospital due to botulism in Utah. Pharmaceutical company Pharmasset Inc. has been acquired by the U.S based biotechnology company Gilead Sciences Inc., derailing the project of Bristol-Myers Squibb Co., a pharmaceutical company.


Related Articles

  • CNYBJ.COM BRIEFS.  // Business Journal (Central New York);8/10/2007, Vol. 21 Issue 32, p10 

    The article offers news briefs related to businesses in New York. Anaren Inc. announced that it has received a $5.8 million contract from Lockheed Martin. Under the contract, Anaren will provide electronic devices that will help U.S. Navy helicopters detect and identify enemy radar....

  • CORPORATE.  // MondayMorning;7/27/2009, Vol. 17 Issue 28, p2 

    The article offers news briefs from the pharmaceutical industry in the U.S. The second quarter earnings posted by Bristol-Myers Squibb Co., New York and Wyeth, Madison, New Jersey, have topped expectations in an otherwise bleak economic scenario. The quarterly profit of Gilead Sciences Inc. has...

  • Truvada combo a no go? Mirasol, Feliza // Chemical Market Reporter;8/22/2005, Vol. 268 Issue 6, p23 

    Reports on Gilead Sciences Inc.'s plan to push forward with the development of a new HIV combination pill joining Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) with Bristol-Myers Squibb Co.'s Sustiva (efavirenz). Clinical setback for Gilead following the failure of a...

  • NEW PRODUCTS.  // Clinician Reviews;Nov2006, Vol. 16 Issue 11, p55 

    The article evaluates several drugs, including Atripla from Bristol-Myers Squibb Co. and Gilead Sciences, Inc., Implanon from Organon USA Inc., and Orapred ODT from Alliant Pharmaceuticals and BioMarin Pharmaceutical Inc.

  • One! Adams, Bob // Out;Summer2005 Thrive, p44 

    Focuses on the collaboration of pharmaceutical firms Bristol-Myers Squibb and Gilead Sciences to produce a once-a-day pill which, if approved by the U.S. Food and Drug Administration, would be the simplest anti-HIV regimen available. Drug components of the pill; Significance of the...

  • Gilead Sciences Licenses Five HIV/AIDS Drugs to New Medicines Patent Pool: The Start of a New Trend? Lane, Jeffrey P. // International Law News;Winter2012, Vol. 41 Issue 1, p27 

    The article reports that in July 2011, Gilead Sciences Inc. became the first pharmaceutical company to license drug technology to the new international Medicines Patent Pool (Pool). It is mentioned that Gilead licensed five of its HIV/AIDS drugs to the Pool, and as many as five other...

  • HIV Treatment in One Daily Pill.  // Guide;Feb2005, Vol. 25 Issue 2, p78 

    Reports on drug firms Bristol-Myers Squibb Co. and Gilead Sciences Inc.'s formation of a joint venture to manufacture and test the once-daily pill containing AIDS medicines Sustiva, Viread and Emtriva.

  • Gilead's Phase III HBV Data: Viread Stacks Up To Hepsera. Osborne, Randall // BioWorld Today;6/8/2007, Vol. 18 Issue 111, p1 

    The article reports that Positive Phase III data with Gilead Sciences Incorporated's Viread for chronic hepatitis B virus (HBV) has left analysts divided on whether marketing the compound could threaten Hepsera further, the company's already-cleared therapy. According to Sharon Seiler, senior...

  • HARD TO SWALLOW. Roehr, Bob // Just Out;1/7/2005, Vol. 22 Issue 5, p15 

    Reports that pharmaceutical firms Bristol-Myers Squibb Co. and Gilead Sciences Inc. have collaborated to produce a single anti-HIV pill that contains multiple drugs. Drugs produced by Bristol and Gilead; Need of clinical trials to demonstrate that packing the drugs all into the same pill results...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics